Chester County News and Community Website
LANGHORNE, PA — PANTHERx Rare Pharmacy and Savara Inc. (Nasdaq: SVRA) announced an exclusive U.S. distribution agreement for MOLBREEVI, an investigational inhaled therapy under FDA review for a rare and …
Rare Lung Drug Nears FDA Decision as PANTHERx, Savara Seal U.S. Deal Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has resubmitted its biologics license application for MOLBREEVI to the U.S. Food and Drug Administration, a key regulatory step toward approval …
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said members of its management team will present and hold one-on-one meetings at the 44th Annual J.P. Morgan Healthcare Conference, a closely watched …
Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug Read More LANGHORNE, PA — Savara Inc. (NASDAQ: SVRA) said European patent authorities have moved to grant a key patent covering the liquid formulation of its investigational lung therapy MOLBREEVI, strengthening the …
Savara Locks In Long-Term Europe Protection for Rare Lung Drug MOLBREEVI Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) will engage investors next week as members of its management team participate in one-on-one meetings and fireside chats at two high-profile healthcare conferences.
Savara to Spotlight Lead Therapy in Fireside Chats at Major Healthcare Conferences Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it remains on track to resubmit its Biologics License Application for MOLBREEVI, a potential first-in-class treatment for autoimmune pulmonary alveolar proteinosis, in …
Savara Advances MOLBREEVI Toward Approval as Financing Boost Extends Cash Runway Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has entered into a $75 million royalty funding agreement with funds managed by RTW Investments, LP, contingent on U.S. Food and Drug Administration …
Savara Secures $75 Million Royalty Deal to Back Potential MOLBREEVI Launch Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) promoted Yasmine Wasfi, M.D., Ph.D., FCCP, to chief medical officer, succeeding Ray Pratt, M.D., FACP, who will become senior medical advisor. Wasfi, formerly …
Savara Elevates Dr. Yasmine Wasfi to CMO as Autoimmune PAP Program Advances Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that its updated analysis of U.S. health claims data estimates approximately 5,500 patients are currently diagnosed with autoimmune pulmonary alveolar proteinosis (autoimmune …
Savara Increases Estimate of Autoimmune PAP Prevalence in U.S., Advances MOLBREEVI Toward FDA Resubmission Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that its management team will participate in two upcoming healthcare conferences in September.
Savara to Present at Two Upcoming Healthcare Conferences Read More